NYSE:WSTLife Sciences
How Investors Are Reacting To West Pharmaceutical (WST) GLP-1 Momentum And Upbeat 2026 Sales Guidance
In February 2026, West Pharmaceutical Services reported that fourth-quarter 2025 sales rose to US$805.0 million with net income of US$132.1 million, and issued 2026 guidance calling for US$3.215–3.275 billion in net sales with mid-single-digit organic growth supported by foreign-exchange tailwinds.
Management highlighted strong momentum in high-value product components tied to GLP-1 therapies and biologics, alongside margin expansion from a richer product mix and a planned sale of the...